Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET

Leukemia and Lymphoma

Volumn 48, Issue 4, 2007, Pages 746-753

  Kasper, Bernd ^a   Egerer, Gerlinde ^a   Gronkowski, Martina ^a   Haufe, Sabine ^a   Lehnert, Thomas ^b   Eisenhut, Michael ^c   Mechtersheimer, Gunhild ^a   Ho, Anthony D ^a   Haberkorn, Uwe ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KLINIKUM BREMEN MITTE   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

18F fluorodeoxyglucose; FLT; Hematology; Lymphoma; Positron emission tomography

Indexed keywords

3' FLUOROTHYMIDINE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; MELPHALAN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC VALUE; DRUG MEGADOSE; FEMALE; HODGKIN DISEASE; HUMAN; MALE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; COMBINED MODALITY THERAPY; DIDEOXYNUCLEOSIDES; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS;

EID: 34247189630     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601113568     Document Type: Article

References (34)

1. De Wit, M., Bumann, D., Beyer, W., Herbst, K., Clausen, M. and Hossfeld, D. K. (1997) Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol, 8, pp. 57-60.
2. Golling, A., Egerer, G. and Lehnert, T. (2000) Chirurgische Maßnahmen in diagnostik und therapie des M. Hodgkin. Onkologie, 6, pp. 1151-1159.
3. Hong, S., Hahn, J., Lee, J., Bae, S. and Youn, M. (2003) 18F-fluorodeoxyglucose positron emission tomography in the staging of malignant lymphoma compared with CT and 67-Ga scan. Yonsei Med J, 44, pp. 779-786.
4. Paul, R. (1987) Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for the detection of lymphoma. J Nucl Med, 28, pp. 288-292.
5. Kostakoglu, L. and Goldsmith, S. (2000) Positron emission tomography in lymphoma: Comparison with computed tomography and gallium-67 single photon emission computed tomography. Clin Lymphoma, 1, pp. 67-74.
6. Kostakoglu, L. and Goldsmith, S. (2003) 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung and colorectal carcinoma. J Nucl Med, 44, pp. 224-239.
7. Haberkorn, U., Strauss, L. G. and Dimitrakopoulou, A. (1991) PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med, 32, pp. 1485-1490.
8. Haberkorn, U., Strauss, L. G. and Dimitrakopoulou, A. (1993) Fluorodeoxyglucose (FDG) imaging of advanced head and neck cancer after chemotherapy. J Nucl Med, 34, pp. 12-17.
9. Jerusalem, G., Beguin, Y., Fassotte, M., Najjar, F., Paulus, P., Rigo, P. and Fillet, G. (1999) Whole body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood, 94, pp. 429-433.
10. Kubota, R., Yamada, S., Kubota, K., Ishiwata, K., Tamahashi, N. and Ido, T. (1992) Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med, 33, pp. 1972-1980.
11. O'Doherty, M., Macdonald, E., Barrington, S., Mikhaeel, N. and Schey, S. (2002) Positron emission tomography in the management of lymphomas. Clin Oncol, 14, pp. 415-426.
12. Mier, W., Haberkorn, U. and Eisenhut, M. (2002) [18F]FLT: Portrait of a proliferation marker. Eur J Nucl Med, 29, pp. 165-169.
13. Shields, A., Grierson, J. and Dohmen, B. (1998) Imaging proliferation in vivo with [F-18] FLT and positron emission tomography. Nat Med, 4, pp. 1334-1336.
14. Dittmann, H., Dohmen, B. M., Kehlbach, R., Bartusek, G., Pritzkow, M., Sarbia, M. and Bares, R. (2002) Early changes in [18F]FLT uptake after chemotherapy: An experimental study. Eur J Nucl Med Mol Imaging, 29, pp. 1462-1469.
15. Wagner, M., Seitz, U. and Buck, A. (2003) 3′-[18F]fluoro-3′-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in amurine B-cell lymphoma model and in the human disease. Cancer Res, 63, pp. 2681-2687.
16. Kaplan, E. and Meier, P. (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53, pp. 457-481.
17. Segall, G. (2001) FDG PET imaging in patients with lymphoma: A clinical perspective. J Nucl Med, 42, pp. 609-610.
18. Hoskin, P. (2002) FDG PET in the management of lymphoma: A clinical perspective. Eur J Nucl Med, 29, pp. 449-451.
19. Lowe, V. and Wiseman, G. (2002) Assessment of lymphoma treatment using 18F-FDG PET. J Nucl Med, 43, pp. 1028-1030.
20. Canellos, G. (1988) Residual mass in lymphoma may not be residual disease. J Clin Oncol, 6, pp. 931-933.
21. Guay, C., Lepine, M., Verreault, J. and Benard, F. (2003) Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med, 44, pp. 1225-1231.
22. De Wit, M., Bohuslavizki, K., Buchert, R., Bumann, D., Clausen, M. and Hossfeld, D. (2001) 18FDG-PET following treatment as valid predictor for disease free survival in Hodgkin's lymphoma. Ann Oncol, 12, pp. 29-37.
23. Weihrauch, M. and Scheidhauer, K. (2001) Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood, 98, pp. 2930-2934.
24. Spaepen, K., Stroobants, S. and Dupont, P. (2002) Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's Lymphoma. Ann Oncol, 13, pp. 1356-1363.
25. Mikhaeel, N., Timothy, A., O'Doherty, M., Hain, S. and Maisey, M. (2000) 18FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT. Leuk Lymphoma, 39, pp. 543-553.
26. Jerusalem, G., Beguin, Y., Fassotte, M., Belhocine, T., Hustinx, R., Rigo, P. and Fillet, G. (2003) Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol, 14, pp. 123-130.
27. Kostakoglu, L., Coleman, M., Leonard, J., Kuji, I., Zoe, H. and Goldsmith, S. (2002) PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med, 43, pp. 1018-1027.
28. Buck, A. K., Halter, G. and Schirrmeister, H. (2003) Imaging prolfieration in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med, 44, pp. 1426-1431.
29. Been, L. B., Suurmeijer, A. J., Cobben, D. C., Jager, P. L., Hoekstra, H. J. and Elsinga, P. H. (2004) [18F]FLT PET in oncology: Current status and opportunities. Eur J Nucl Med Mol Imaging, 31, pp. 1659-1672.
30. Tominaga, K., Yamaguchi, Y., Nozawa, A., Abe, M. and Wakasa, H. (1992) Proliferation in non-Hodgkin's lymphomas as determined by immunohistochemical double staining for Ki-67. Hematol Oncol, 10, pp. 163-169.
31. Dittmann, H., Dohmen, B. M. and Paulsen, F. (2003) [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging, 30, pp. 1407-1412.
32. Smyczek-Gargya, B., Fersis, N. and Dittmann, H. (2004) PET with [18F]fluorothymidine for imaging of primary breast cancer: A pilot study. Eur J Nucl Med Mol Imaging, 31, pp. 720-724.
33. Leskinen-Kallio, S., Ruotsalainen, U., Nagren, K., Teras, M. and Joensuu, H. (2003) Uptake of 18F-fluoro-tyrosine: Preliminary evaluation and comparison with 18F-FDG. J Nucl Med, 44, pp. 533-539.
34. Hustinx, R., Lemaire, C. and Jerusalem, G. (2003) Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: Preliminary evaluation and comparison with 18F-FDG. J Nucl Med, 44, pp. 533-539.